禾元生物：用“种药”逻辑掀起技术革命

Core Viewpoint - The approval of HY1001, a core product of Wuhan Heyuan Biotechnology Co., Ltd., will effectively alleviate China's long-term reliance on imported human serum albumin [2][5]. Group 1: Company Overview - Wuhan Heyuan Biotechnology has been focusing on recombinant protein expression technology research and product development since its establishment in 2006 [2][8]. - The company has developed a complete and advanced technical system, with the Oryz HiExp platform for efficient recombinant protein expression and the Oryz Pur platform for protein purification as its core competitive advantages [2][4]. Group 2: Technical Platforms - The Oryz HiExp platform utilizes rice endosperm cells as bioreactors, achieving a significant increase in recombinant protein yield from milligram levels to 30 grams, enhancing production efficiency [3]. - The Oryz Pur platform is designed for the purification of recombinant proteins, capable of producing high-purity, high-activity proteins with low host protein and nucleic acid residues, scalable from milligrams to tons [4]. Group 3: Product Pipeline - In addition to HY1001, the company has a rich product pipeline with multiple pharmaceutical products at various research stages [5]. - HY1001 has shown comparable efficacy and good safety in Phase III clinical studies, addressing the limitations of human plasma-derived human serum albumin [5]. Group 4: Industry Impact - Heyuan Biotechnology's innovations provide a new model for raw material production in the biopharmaceutical industry, reducing dependence on scarce resources like plasma and offering a greener, safer, and more sustainable production method [7]. - The company's high-quality recombinant protein products can enhance drug targeting and efficacy, accelerating new drug development processes [7]. Group 5: Research and Development - The company has made significant R&D investments, totaling 386.38 million yuan from 2022 to 2024, and collaborates with domestic and international research institutions to accelerate technological breakthroughs [8]. - Supported by national policies, Heyuan Biotechnology is poised to become a key player in driving industry transformation and providing safe, effective biopharmaceutical products globally [8].